Summary of Organon & Co. Conference Call Company Overview - **Company**: Organon & Co. (NYSE: OGN) - **Event**: 4th Annual Evercore ISI HealthCONx Conference - **Date**: December 1, 2021 Key Points Company Performance and Strategy - Organon is six months post-spin-off and has successfully executed a complex separation from its parent company, Merck [3] - The company anticipates organic revenue growth in the low to mid-single digits, driven by focused management and investment in its assets [4][15] - Organon has three business segments: established brands, biosimilars, and women's health, with a strong focus on becoming a global leader in women's health [5][6] Women's Health Business - The women's health segment has expanded its portfolio to include postpartum hemorrhage, pre-term labor, endometriosis, and polycystic ovary syndrome through acquisitions [5] - Nexplanon, a key product in the women's health segment, is expected to maintain strong sales, potentially exceeding $1 billion in revenue [20] - The company is exploring price increases for Nexplanon post-2025, following the completion of a five-year efficacy study [24][26] Biosimilars - The HUMIRA biosimilar launch is a significant opportunity for Organon, with ongoing discussions to expand its portfolio in immunology and oncology [41][42] - The company expects to maintain a competitive edge in the biosimilars market through strategic partnerships and new product launches [42][46] Financial Outlook - Margins in Q3 were strong, but the company anticipates pressure on margins due to increased R&D expenses and operational costs as it scales up its pipeline [12][70] - Guidance for 2022 will be provided early in the year, with expectations of stable EBITDA in absolute dollars despite potential margin compression [72][76] Market Conditions - The company is monitoring inflationary pressures on raw materials but believes it can offset these through operational efficiencies [8][10] - Organon is confident in its growth prospects in China, where the retail sector has shown strong double-digit growth [53] Acquisition Strategy - Organon is actively pursuing acquisition opportunities, particularly in the women's health space, to enhance its product offerings and pipeline [60][62] - The company has established strong relationships with Merck, facilitating potential collaborations on future projects [38] Other Considerations - The company is focused on lifecycle management and geographic expansion, including OTC product launches in Russia [57] - Organon is committed to a balanced approach in business development, targeting both early-stage and mid-to-late-stage assets [60] Conclusion Organon & Co. is positioned for steady growth in the women's health and biosimilars markets, with a strategic focus on acquisitions and operational efficiency. The company is navigating inflationary pressures while preparing for a stable financial outlook in 2022.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified in its charter) ...

Organon & Co. (NYSE:OGN) Q3 2021 Results Conference Call November 11, 2021 8:30 AM ET Company Participants Kevin Ali – Chief Executive Officer Matt Walsh – Chief Financial Officer Jennifer Halchak – Vice President, Investor Relations Conference Call Participants Chris Schott – JP Morgan Navann Ty – Citi Umer Raffat – Evercore Steven Scala – Cowen Greg Fraser – Truist Securities Ashville with Bank – America Charlie Yang – Morgan Stanley David Amsellem – Piper Jaffray Operator Ladies and gentlemen, thank you ...

Organon Q3 2021 Earnings · · · ORGANON™ Disclaimer statement This text should be viewed in conjunction with Organon's Q3 2021 earnings call Safe Harbor for Forward-Looking Statements Except for the historical information herein, this presentation of Organon & Co. (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified in its charter) Delawar ...

Organon & Co (NYSE:OGN) Q2 2021 Earnings Conference Call August 12, 2021 8:30 AM ET Company Participants Jennifer Halchak – Vice President of Investor Relations Kevin Ali – Chief Executive Officer Matt Walsh – Chief Financial Officer Conference Call Participants Terence Flynn – Goldman Sachs Navann Ty – Citi Greg Fraser – Truist Securities Charlie Yang – Morgan Stanley Umer Raffat – Evercore ISI Steve Scala – Cowen Operator Good day and thank you for standing by. Welcome to the Organon's Second Quarter Earn ...

Organon Q2 2021 Earnings ·炉 ORGANON Disclaimer statement 2 This text should be viewed in conjunction with Organon's Q2 2021 earnings call Safe Harbor for Forward-Looking Statements Exc p f r h h s r c l f rm h r h s pr s f Org & . ( h "c mp y") cl s "f rw r -looking statem s" w h h meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements m g m 's xp c s Org 's f r f c l p rf rm c pr sp c s. F rw r -looking statements may be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified in its charter) Del ...